Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jhanelle E Gray

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Cancer Genetics|June 13, 2015
BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancerJamie M Goldman, Jhanelle E Gray
Expert Review of Respiratory Medicine|August 9, 2017
Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agentsSonam Puri, Monica Chatwal, Jhanelle E Gray
Current Treatment Options in Oncology|June 23, 2018
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung CancerSonam Puri, Michael Shafique, Jhanelle E Gray
Journal of Thoracic Disease|March 30, 2018
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancerSandrine Niyongere, Andreas Saltos, Jhanelle E Gray
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung CancerKristin A Higgins, Sonam Puri, Jhanelle E Gray
JCO Oncology Practice|December 10, 2025
Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based AnalysisTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Clinical Lung Cancer|June 2, 2024
Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based AnalysisTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Journal of Clinical Medicine|May 13, 2026
HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative DiseaseTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Clinical Lung Cancer|November 14, 2025
Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab ConsolidationTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Expert Opinion on Biological Therapy|January 10, 2017
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?Tawee Tanvetyanon, Jhanelle E Gray, Scott J Antonia
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Cancer Genetics|June 13, 2015
BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancerJamie M Goldman, Jhanelle E Gray
Expert Review of Respiratory Medicine|August 9, 2017
Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agentsSonam Puri, Monica Chatwal, Jhanelle E Gray
Current Treatment Options in Oncology|June 23, 2018
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung CancerSonam Puri, Michael Shafique, Jhanelle E Gray
Journal of Thoracic Disease|March 30, 2018
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancerSandrine Niyongere, Andreas Saltos, Jhanelle E Gray
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung CancerKristin A Higgins, Sonam Puri, Jhanelle E Gray
JCO Oncology Practice|December 10, 2025
Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based AnalysisTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Clinical Lung Cancer|June 2, 2024
Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based AnalysisTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Journal of Clinical Medicine|May 13, 2026
HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative DiseaseTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Clinical Lung Cancer|November 14, 2025
Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab ConsolidationTawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray
Expert Opinion on Biological Therapy|January 10, 2017
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?Tawee Tanvetyanon, Jhanelle E Gray, Scott J Antonia
Pageof 14